{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:34:28Z","timestamp":1773470068082,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.urology.2022.06.012","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T02:01:03Z","timestamp":1656381663000},"page":"137-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2043-3658","authenticated-orcid":false,"given":"Tarik","family":"Benidir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-1948","authenticated-orcid":false,"given":"Zaeem","family":"Lone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S.","family":"Nowacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Munoz-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranay","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Fajnzylber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Abouassaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Eltemamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihad","family":"Kaouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Weight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Almassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Pascal-Haber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2022.06.012_bib0001","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2022.06.012_bib0002","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2003.09.019","article-title":"Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies","volume":"45","author":"Sherif","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0003","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"Group the NCI of CCT, Finnbladder NBCSG, Group CUE de TO. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: long-term results of the BA06 30894 Trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2022.06.012_bib0004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/003655902762467567","article-title":"Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer \u2013 Nordic cystectomy trial 2","volume":"36","author":"Sherif","year":"2002","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.urology.2022.06.012_bib0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0006","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","article-title":"Neoadjuvant Gemcitabine-Cisplatin plus radical cystectomy-pelvic lymph node dissection for muscle-invasive bladder cancer: a 12-year experience","volume":"18","author":"Iyer","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urology.2022.06.012_bib0007","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.juro.2013.07.061","article-title":"Refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"191","author":"Culp","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0008","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/JU.0000000000001943","article-title":"Progression of disease after bacillus Calmette-Gu\u00e9rin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"206","author":"Hensley","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0009","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bju.15428","article-title":"Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy","volume":"129","author":"Almassi","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2022.06.012_bib0010","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","article-title":"Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma","volume":"124","author":"Teo","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2022.06.012_bib0011","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clgc.2020.07.011","article-title":"Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities","volume":"19","author":"Deuker","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urology.2022.06.012_bib0012","first-page":"3","article-title":"The impact of variant histology on the outcome of bladder cancer treated with curative intent","volume":"27","author":"Black","year":"2009","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.urology.2022.06.012_bib0013","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2022.06.012_bib0014","doi-asserted-by":"crossref","first-page":"692","DOI":"10.21037\/tau.2016.06.13","article-title":"Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?","volume":"5","author":"Klaile","year":"2016","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0015","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urology.2022.06.012_bib0016","first-page":"9","article-title":"Molecular and clinical insights into the role and significance of mutated DNA repair genes in bladder cancer","volume":"4","author":"Abbosh","year":"2018","journal-title":"Bl cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.urology.2022.06.012_bib0017","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0018","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0019","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000107950","article-title":"Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate","volume":"79","author":"Ferreira","year":"2007","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2022.06.012_bib0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00345-012-0832-2","article-title":"Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?","volume":"30","author":"Kotb","year":"2012","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0021","first-page":"274","article-title":"Effect of treatment modality on long term renal functions in patients with muscle invasive bladder cancer","volume":"16","author":"Hamidi","year":"2019","journal-title":"Urol J"},{"key":"10.1016\/j.urology.2022.06.012_bib0022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005392-200101000-00012","article-title":"De novo muscle invasive bladder cancer: is there a change in trend?","volume":"165","author":"Vaidya","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0023","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1464-4096.2001.001020.x","article-title":"Outcome of radical cystectomy for bladder cancer according to the disease type at presentation","volume":"89","author":"Yiou","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2022.06.012_bib0024","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejso.2009.11.012","article-title":"Survival after cystectomy for invasive bladder cancer","volume":"36","author":"de Vries","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urology.2022.06.012_bib0025","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bju.12403","article-title":"Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis","volume":"113","author":"Breau","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2022.06.012_bib0026","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000350232","article-title":"Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy","volume":"91","author":"Aziz","year":"2013","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2022.06.012_bib0027","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2022.06.012_bib0028","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7150\/ijms.49228","article-title":"Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: an updated meta-analysis","volume":"18","author":"Zheng","year":"2021","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.urology.2022.06.012_bib0029","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.urology.2022.06.012_bib0030","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.28147","article-title":"Recurrence of high-risk bladder cancer: a population-based analysis","volume":"119","author":"Chamie","year":"2013","journal-title":"Cancer"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522005143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522005143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:47:58Z","timestamp":1758768478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429522005143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":30,"alternative-id":["S0090429522005143"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2022.06.012","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2022.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}